{"id":"NCT03963232","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Galcanezumab in Patients With Episodic Migraine-the Persist Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-07-30","primaryCompletion":"2021-07-27","completion":"2022-03-11","firstPosted":"2019-05-24","resultsPosted":"2022-08-19","lastUpdate":"2023-03-28"},"enrollment":520,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Episodic Migraine"],"interventions":[{"type":"DRUG","name":"Galcanezumab","otherNames":["LY2951742"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Galcanezumab 120 mg","type":"EXPERIMENTAL"}],"summary":"The reason for this study is to see if the drug galcanezumab is safe and effective in participants with episodic migraine. The study will last about 53 weeks and may include up to 12 visits.","primaryOutcome":{"measure":"Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (MHDs) During the Double-blind Treatment Phase.","timeFrame":"Baseline, 3 Months","effectByArm":[{"arm":"Placebo - Double-Blind Treatment Phase","deltaMin":-1.99,"sd":0.23},{"arm":"Galcanezumab 120mg - Double-Blind Treatment Phase","deltaMin":-3.81,"sd":0.23}],"pValues":[{"comp":"OG000 vs OG001","p":"<.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":6},"locations":{"siteCount":40,"countries":["China","India","Russia"]},"refs":{"pmids":["37542222","35896988"],"seeAlso":["https://trials.lillytrialguide.com/en-US/trial/31dBGbS2DbVt4INep01n59"]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":259},"commonTop":["Injection site pain","Upper respiratory tract infection"]}}